Mesoblast International SARL
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 1, 2027The maintenance fee for Method for Treating Heart Failure (US 11,712,452) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due Mar 3, 2027The maintenance fee for Improved Stem Cell Composition (US 10,400,218) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
- 1 fee due Apr 24, 2027The maintenance fee for Potency Assay (US 11,795,435) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Enhanced MSC Preparation (US 10,550,369) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Treatment of Immune Disorders (US 10,624,930) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Oct 13 US 12,760,276 Expansion of Hematopoietic Stem Cells
- 1 term has ended since Aug 23, 2026
- Sep 15 US 11,389,484 Mesenchymal Stem Cells and Uses Therefor · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,828,586 | Enhanced MSC Preparations In force · Medium confidence | In force | Medium confidence | |
| US 9,963,678 | Enhanced MSC Preparations In force · Low confidence | In force | Low confidence | |
| US 10,550,369 | Enhanced MSC Preparation In force · Medium confidence | In force | Medium confidence | |
| US 10,400,218 | Improved Stem Cell Composition In force · High confidence | In force | High confidence | |
| US 11,312,941 | Stem Cell Composition In force · High confidence | In force | High confidence | |
| US 12,616,722 | Treatment of Immune Disorders In force · High confidence | In force | High confidence | |
| US 10,624,930 | Treatment of Immune Disorders In force · High confidence | In force | High confidence | |
| US 12,257,270 | Treatment of Immune Disorders In force · Low confidence | In force | Low confidence | |
| US 11,491,188 | Prevention of Progressive Heart Failure In force · High confidence | In force | High confidence | |
| US 11,712,452 | Method for Treating Heart Failure In force · High confidence | In force | High confidence |
Also on record, not counted in the 18: 3 patents in force now held by others · 15 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 6 abandoned